QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.060459v1 308/3/1130    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonaventure, P. Articles by Lovenberg, T. W. Search for Related Content PubMed PubMed Citation Articles by Bonaventure, P. Articles by Lovenberg, T. W.

NEUROPHARMACOLOGY

Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y₂ Receptor

Johnson & Johnson Pharmaceutical Research and Development, San Diego, California

The in vitro pharmacological properties of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]-acrylamide (JNJ-5207787), a novel neuropeptide Y Y₂ receptor (Y₂) antagonist, were evaluated. JNJ-5207787 inhibited the binding of peptide YY (PYY) to human Y₂ receptor in KAN-Ts cells (pIC₅₀ = 7.00 ± 0.10) and to rat Y₂ receptors in rat hippocampus (pIC₅₀ = 7.10 ± 0.20). The compound was >100-fold selective versus human Y₁,Y₄, and Y₅ receptors as evaluated by radioligand binding. In vitro receptor autoradiography data in rat brain tissue sections confirmed the selectivity of JNJ-5207787. [¹²⁵I]PYY binding sites sensitive to JNJ-5207787 were found in rat brain regions known to express Y₂ receptor (septum, hypothalamus, hippocampus, substantia nigra, and cerebellum), whereas insensitive binding sites were observed in regions known to express Y₁ receptor (cortex and thalamus). JNJ-5207787 was demonstrated to be an antagonist via inhibition of PYY-stimulated guanosine 5'-O-(3-[³⁵S]thio)triphosphate binding ([³⁵S]GTPS) in KAN-Ts cells (pIC₅₀ corrected = 7.20 ± 0.12). This was confirmed auto-radiographically in rat brain sections where PYY-stimulated guanosine 5'-O-(3-[³⁵S]thio)triphosphate binding was inhibited by JNJ-5207787 (10 µM) in hypothalamus, hippocampus, and substantia nigra. After intraperitoneal administration in rats (30 mg/kg), JNJ-5207787 penetrated into the brain (C_max = 1351 ± 153 ng/ml at 30 min) and occupied Y₂ receptor binding sites as revealed by ex vivo receptor autoradiography. Hence, JNJ-5207787 is a potent and selective pharmacological tool available to establish the potential role of central and peripheral Y₂ receptors in vivo.

Address correspondence to: Dr. Pascal Bonaventure, Johnson & Johnson Pharmaceutical Research and Development, 3210 Merryfield Row, San Diego, CA 92121. E-mail: pbonave1{at}prdus.jnj.com

This article has been cited by other articles:

				I. Gantz, N. Erondu, M. Mallick, B. Musser, R. Krishna, W. K. Tanaka, K. Snyder, C. Stevens, M. A. Stroh, H. Zhu, et al. Efficacy and Safety of Intranasal Peptide YY3-36 for Weight Reduction in Obese Adults J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1754 - 1757. [Abstract] [Full Text] [PDF]

				Y. Dumont, E. Moyse, A. Fournier, and R. Quirion Evidence for the Existence of an Additional Class of Neuropeptide Y Receptor Sites in Rat Brain J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 99 - 108. [Abstract] [Full Text] [PDF]